# Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

> **NCT00096018** · PHASE1,PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 43 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** fludarabine phosphate
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00096018
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2010-11
- **Final completion:** 2012-05
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2013-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096018, "Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00096018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*